T
Therapix Biosciences
Development of synthetic cannabinoid-based therapies for cancer-related and other chronic pain conditions, rheumatoid arthritis, and neurodegenerative diseases
About Therapix Biosciences
Therapix Biosciences is a specialty pharmaceutical company focused on developing unique cannabinoid-based technologies for the treatment of central nervous system (CNS) disorders. The company operates in the biopharmaceutical sector, targeting conditions such as epilepsy, Alzheimer's disease, and other neurological disorders. Therapix serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. Therapix's business model revolves around research and development (R&D) of proprietary cannabinoid formulations, which are then licensed out or sold to larger pharmaceutical companies for further development and commercialization. This model allows Therapix to generate revenue through licensing fees, milestone payments, and royalties on sales of the final products. The company also aims to bridge the financial gap for other biopharmaceutical companies by providing advisory services and financial support, leveraging its expertise and network within the industry. Therapix is committed to advancing the science of cannabinoids and their therapeutic potential, positioning itself as a leader in this niche market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2004
- Headquarters
- Tel Aviv-Yafo, Israel
- Listing
- IPO 2017
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Oncology, Cannabis, Chronic Disease, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Apr 2014
- Capital deployed
- $1.5M
- Preferred round
- EARLY VC
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Oct 2023 | $5M | — | Undisclosed | ↗ |
| GROWTH EQUITY VCEquity / VC | May 2022 | $10M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Therapix Biosciences is 100 monthly website visits, down 66.7% over the last three months. Therapix Biosciences's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Quantum BioPharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Therapix Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Therapix Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.